Publicação
As controvérsias da vacina contra o HPV
| Resumo: | Background: Human papillomavirus (HPV) is one of the most widespread sexually transmitted diseases in the world. It is estimated that at least 50% of all sexually active people are infected during their lifetime. HPV16 and HPV18 account for about 70% of cases of cervical cancer.The emergence of the HPV vaccine, tested worldwide and approved by the FDA in 2006, has generated controversy early on. Currently, there are three commercial HPV vaccines on the market: Gardasil®, CervarixTM, and more recently Gardasil9®. These are prophylactic vaccines, without therapeutic efficacy.Objectives: This review intends to address the controversies of HPV vaccine, based on the bibliographical research of recent publications, so that it can be an updated auxiliary information instrument for clinical practice.Data Sources: Search of articles on PubMed®, b-on®, UpToDate® and service of the Biblioteca das Ciências da Saúde da Universidade de Coimbra, being extended with consultation of bibliographical references considered of interest.Review methods: Of the 229 articles obtained, 117 were selected by reading abstract, which corresponded to the objective of this review, as well as other studies that could give a general approach to this issue.Conclusions: The development of HPV vaccine represents a milestone in the prevention of HPV related infections, lesions and cancers related. A new generation of vaccine currently being marketed and initial studies have found them to be highly effective. However the available vaccines are safe and are also effective (>90%) but their true effect can only be confirmed following a 20 year follow-up period. The actual long term effectiveness and safety of the vaccine is not yet known. As a result, HPV screening still has a major role to play invcancer prevention. The next vaccine generations should not only be more effective, with a bigger coverage, but also cheaper and will try to create a therapeutic capacity vaccine. |
|---|---|
| Autores principais: | Vaz, Susan Sofia Gonçalves |
| Assunto: | Papillomavirus humano Vacinas de Papillomavírus Infeções por Papillomavírus Carcinoma do Colo do útero Viral like particles Human papillomavirus Papillomavirus Vaccines Papillomavirus infections Uterine Cervical Neoplasms Viral like particles |
| Ano: | 2017 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso embargado |
| Instituição associada: | Universidade de Coimbra |
| Idioma: | português |
| Origem: | Estudo Geral - Universidade de Coimbra |
| Resumo: | Background: Human papillomavirus (HPV) is one of the most widespread sexually transmitted diseases in the world. It is estimated that at least 50% of all sexually active people are infected during their lifetime. HPV16 and HPV18 account for about 70% of cases of cervical cancer.The emergence of the HPV vaccine, tested worldwide and approved by the FDA in 2006, has generated controversy early on. Currently, there are three commercial HPV vaccines on the market: Gardasil®, CervarixTM, and more recently Gardasil9®. These are prophylactic vaccines, without therapeutic efficacy.Objectives: This review intends to address the controversies of HPV vaccine, based on the bibliographical research of recent publications, so that it can be an updated auxiliary information instrument for clinical practice.Data Sources: Search of articles on PubMed®, b-on®, UpToDate® and service of the Biblioteca das Ciências da Saúde da Universidade de Coimbra, being extended with consultation of bibliographical references considered of interest.Review methods: Of the 229 articles obtained, 117 were selected by reading abstract, which corresponded to the objective of this review, as well as other studies that could give a general approach to this issue.Conclusions: The development of HPV vaccine represents a milestone in the prevention of HPV related infections, lesions and cancers related. A new generation of vaccine currently being marketed and initial studies have found them to be highly effective. However the available vaccines are safe and are also effective (>90%) but their true effect can only be confirmed following a 20 year follow-up period. The actual long term effectiveness and safety of the vaccine is not yet known. As a result, HPV screening still has a major role to play invcancer prevention. The next vaccine generations should not only be more effective, with a bigger coverage, but also cheaper and will try to create a therapeutic capacity vaccine. |
|---|
Atividades financiadas
Não foram encontrados projetos financiados.